Global Peptide Therapeutics Pipeline Insight 2015

Publish Date:- Feb-2015       No Of Pages (1200)

Electronic Access - Single User License $2400 Buy Now
CD-ROM Mail Delivery $3000Buy Now
Hard Copy Mail Delivery $3600 Buy Now
Electronic Access - Multi-User License $4800 Buy Now


Peptides are small molecules of varying molecular masses that consist of amino acids joined with the help of peptide bonds (CONH2). One end of the molecule consists of carboxyl (COOH2) group while the other end has amino (NH2) group giving rise to polarity. Biologically, they are very important and found to play an important role in various anabolic and catabolic processes. They are essential component of cell signaling pathways, immune system, hormonal systems, enzymatic systems and others important systems in the body. Owing to same building blocks, sometimes they are confused with the proteins which are more or less biochemically similar in nature. Technically, peptide consists of upto 50 amino acids in the chain while proteins are much longer chains of amino acids.

Researchers have identified several peptides which are necessary part of body systems that could be used for pharmacological purposes during disease incidence. Peptides could be easily designed and modified according to necessity due to which they have high safety and efficacy profile. They are small in size due to which they can easily enter inside the cell and interact with desired molecules. They have low immunotoxicity due to which they have high tolerability and could be administered to patient of all age group. Various routes of delivery could be observed in this category; they could be injected or orally administrated to patients and newer methods like inhalation is presently under investigation. High bioavailability makes them highly potent as they are highly absorbable due to which lesser amount of therapeutics is required.

Use of peptides in several disease indications has been already proved by investigators and several of them are already available in market. Rapid introduction in market has become possible due to development of high yielding SPPS and LPPS methods. Both have same function of peptide synthesis but they differ in biochemistry due to which their commercial utilization severely depends upon quantity, molecular weight, length of peptide and cost arbitrage. Purification costs also vary from process to process due which it becomes imperative to have effective method that can save time and money. Industrial biotechnologists are working with different modalities to develop new methods having fewer investments per unit peptide therapeutics produced per batch.

Peptide based therapeutics have highly diverse market with numerous categories that could be further divided into several sub categories. They have high market penetration rates across the globe and generate significant amount of revenues. Burgeoning pressure on pharmaceutical companies to come forth with highly effective therapeutic products along with higher cost arbitrage is driving the peptide based therapeutics market. Strong clinical pipeline allows the pharmaceutical companies to regularly introduce their products in global market. Both extreme ends could be observed in this segment reflecting divergence and interest of pharmaceutical companies. Some categories like insulin are quite mature while peptide cancer vaccine market segment is still emerging and has to pass through various phases of industry life cycle.

 

Peptide Segment Included In Report:

 

Cyclic-Peptide, Polypeptide, Glycopeptide, Glycopeptide, Oligopeptide, Depsipeptide, Neuropeptide, Dipeptides, Natriuretic Peptide, Lipopeptide, Opioid Peptide, Peptide Vaccine, Antimicrobial Cationic Peptide & Insulin

 

“Global Peptide Therapeutics Pipeline Insight 2015” Report Highlights: 

  • Global Peptide Therapeutics Market Overview
  • Global Peptide Therapeutics Pipeline By Peptide Type
  • Global Peptide Therapeutics Pipeline By Company, Indication & Phase
  • Peptide Therapeutics Clinical Pipeline: 743 Peptides
  • Majority Peptide Therapeutics in Preclinical Phase: 293 Peptides
  • Commercially available Peptides: 126 Peptides


Peptides are small molecules of varying molecular masses that consist of amino acids joined with the help of peptide bonds (CONH2). One end of the molecule consists of carboxyl (COOH2) group while the other end has amino (NH2) group giving rise to polarity. Biologically, they are very important and found to play an important role in various anabolic and catabolic processes. They are essential component of cell signaling pathways, immune system, hormonal systems, enzymatic systems and others important systems in the body. Owing to same building blocks, sometimes they are confused with the proteins which are more or less biochemically similar in nature. Technically, peptide consists of upto 50 amino acids in the chain while proteins are much longer chains of amino acids.

Researchers have identified several peptides which are necessary part of body systems that could be used for pharmacological purposes during disease incidence. Peptides could be easily designed and modified according to necessity due to which they have high safety and efficacy profile. They are small in size due to which they can easily enter inside the cell and interact with desired molecules. They have low immunotoxicity due to which they have high tolerability and could be administered to patient of all age group. Various routes of delivery could be observed in this category; they could be injected or orally administrated to patients and newer methods like inhalation is presently under investigation. High bioavailability makes them highly potent as they are highly absorbable due to which lesser amount of therapeutics is required.

Use of peptides in several disease indications has been already proved by investigators and several of them are already available in market. Rapid introduction in market has become possible due to development of high yielding SPPS and LPPS methods. Both have same function of peptide synthesis but they differ in biochemistry due to which their commercial utilization severely depends upon quantity, molecular weight, length of peptide and cost arbitrage. Purification costs also vary from process to process due which it becomes imperative to have effective method that can save time and money. Industrial biotechnologists are working with different modalities to develop new methods having fewer investments per unit peptide therapeutics produced per batch.

Peptide based therapeutics have highly diverse market with numerous categories that could be further divided into several sub categories. They have high market penetration rates across the globe and generate significant amount of revenues. Burgeoning pressure on pharmaceutical companies to come forth with highly effective therapeutic products along with higher cost arbitrage is driving the peptide based therapeutics market. Strong clinical pipeline allows the pharmaceutical companies to regularly introduce their products in global market. Both extreme ends could be observed in this segment reflecting divergence and interest of pharmaceutical companies. Some categories like insulin are quite mature while peptide cancer vaccine market segment is still emerging and has to pass through various phases of industry life cycle.

 

Peptide Segment Included In Report:

 

Cyclic-Peptide, Polypeptide, Glycopeptide, Glycopeptide, Oligopeptide, Depsipeptide, Neuropeptide, Dipeptides, Natriuretic Peptide, Lipopeptide, Opioid Peptide, Peptide Vaccine, Antimicrobial Cationic Peptide & Insulin

 

“Global Peptide Therapeutics Pipeline Insight 2015” Report Highlights: 

  • Global Peptide Therapeutics Market Overview
  • Global Peptide Therapeutics Pipeline By Peptide Type
  • Global Peptide Therapeutics Pipeline By Company, Indication & Phase
  • Peptide Therapeutics Clinical Pipeline: 743 Peptides
  • Majority Peptide Therapeutics in Preclinical Phase: 293 Peptides
  • Commercially available Peptides: 126 Peptides

1. Introduction to Peptides

 

2. Mechanism of Peptide Therapeutics

 

3. Global Peptide Therapeutics Market Overview

  3.1 Current Market Scenario

  3.2 Peptide Pipeline Overview

 

4. Global Peptide Therapeutics Market Dynamics

  4.1 Market Growth Drivers

  4.2 Commercialization Challenges

 

5. Global Peptide Therapeutics Market Future Prospects

 

6. Insulin Pipeline by Company, Indication & Phase

  6.1 Phase Research to till Registered

  6.2 Marketed

 

7. Peptides Pipeline by Company, Indication & Phase

  7.1 Phase Research to till Registered

  7.2 Marketed

 

8. Cyclic Peptides Pipeline by Company, Indication & Phase

  8.1 Phase Research to till Preregistration

  8.2 Marketed

 

9. Polypeptide Pipeline by Company, Indication & Phase

  9.1 Phase Research to till Phase-III

  9.2 Marketed

 

10. Glycopeptide Pipeline by Company, Indication & Phase

  10.1 Phase Research to till Registered

  10.2 Marketed

 

11. Lipopeptides Pipeline by Company, Indication & Phase

  11.1 Phase Research to till Phase-III

  11.2 Phase: Marketed

 

12. Oligopeptide Pipeline by Company, Indication & Phase

  12.1 Phase Research to till Preregistration

  12.2 Marketed

 

13. Depsi Peptide Pipeline by Company, Indication & Phase

  13.1 Phase Research to till Phase-III

  13.2 Marketed

 

14. Neuropeptide Pipeline by Company, Indication & Phase

  14.1 Phase Preclinical to till Phase-II/III

  14.2 Marketed

 

15. Dipeptides Pipeline by Company, Indication & Phase

  15.1 Phase Preclinical to till Phase-III

  15.2 Marketed

 

16. Natriuretic Peptide Pipeline by Company, Indication & Phase

  16.1 Phase Preclinical to till Phase-III

 

17. Opioid Peptide Pipeline by Company, Indication & Phase

  17.1 Phase Preclinical to till Preregistration

  17.2 Marketed

 

18. Peptide Vaccine Pipeline by Company, Indication & Phase

  18.1 Phase Preclinical to till Phase-III

 

19. Antimicrobial Cationic Peptide Pipeline by Company, Indication & Phase

  19.1 Phase Preclinical to till Phase-III

 

 

20. Multiple Peptides Pipeline by Company, Indication & Phase

  20.1 Phase Preclinical to till Registered

  20.2 Marketed

 

21. Competitive Landscape

  21.1 Amgen

  21.2 Amylin Pharmaceuticals

  21.3 Corden Pharma (Peptisyntha)

  21.4 GlaxoSmithKline

  21.5 Ipsen

  21.6 Lonza

  21.7 Merck 

  21.8 PeptiDream

  21.9 Roche

  21.10 Sanofi


Figure 1-1: Components of Peptide

Figure 1-2: Features of Peptide Therapeutics

Figure 2-1: Benefits of Peptide Modifications

Figure 2-2: Benefits of Computational Methods

Figure 2-3: Different Types of Peptide Formulation Vehicles

Figure 2-4: Mechanism of Vibativ

Figure 2-5: Mechanism of Liraglutide

Figure 2-6: Mechanism of Goserelin

Figure 2-7: Formulation of Orally Administrated Peptide Therapeutics

Figure 3-1: Global Peptide Market (US$ Billion), 2013-2018

Figure 3-2: Insulin Pipeline by Phase (%), 2015

Figure 3-3: Insulin Pipeline by Phase (Number), 2015

Figure 3-4: Peptides Pipeline by Phase (%), 2015

Figure 3-5: Peptides Pipeline by Phase (Number), 2015

Figure 3-6: Cyclic Peptide Pipeline by Phase (%), 2015

Figure 3-7: Cyclic Peptide Pipeline by Phase (Number), 2015

Figure 3-8: Polypeptide Pipeline by Phase (%), 2015

Figure 3-9: Polypeptide Pipeline by Phase (Number), 2015

Figure 3-10: Glycopeptide Pipeline by Phase (%), 2015

Figure 3-11: Glycopeptide Pipeline by Phase (Number), 2015

Figure 3-12: Lipopeptide Pipeline by Phase (%), 2015

Figure 3-13: Lipopeptide Pipeline by Phase (Number),2014

Figure 3-14: Oligopeptide Pipeline by Phase (%), 2015

Figure 3-15: Oligopeptide Pipeline by Phase (Number), 2015

Figure 3-16: Depsi Peptide Pipeline by Phase (%), 2015

Figure 3-17: Depsi Peptide Pipeline by Phase (Number), 2015

Figure 3-18: Neuropeptide Pipeline by Phase (%), 2015

Figure 3-19: Neuropeptide Pipeline by Phase (Number), 2015

Figure 3-20: Dipeptide Pipeline by Phase (%), 2015

Figure 3-21: Dipeptide Pipeline by Phase (Number), 2015

Figure 3-22: Natriuretic Peptide Pipeline by Phase (%), 2015

Figure 3-23: Natriuretic Peptide Pipeline by Phase (Number), 2015

Figure 3-24: Opioid Peptide Pipeline by Phase (%), 2015

Figure 3-25: Opioid Peptide Pipeline by Phase (Number), 2015

Figure 3-26: Peptide Vaccine Pipeline by Phase (%), 2015

Figure 3-27: Peptide Vaccine Pipeline by Phase (Number), 2015

Figure 3-28: Antimicrobial-Cationic-Peptide Pipeline by Phase (%), 2015

Figure 3-29: Antimicrobial-Cationic-Peptide Pipeline by Phase (Number), 2015

Figure 3-30: Multiple Peptide Pipeline by Phase (%), 2015

Figure 3-31: Multiple Peptide Pipeline by Phase (Number), 2015

Figure 4-1: Global Peptide Therapeutics Market Growth Drivers

Figure 4-2: Global Peptide Therapeutics Market Commercialization Challenges